JP2003093019A - Composition for ingestion in which bifidobacterium longum and xylo-oligosacharide are formulated - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a composition for ingestion having both of excellent symbiotic function and storage property. SOLUTION: This composition for ingestion is obtained by formulating a composition for ingestion of bifidobacterium, preferably bifidobacterium longum with xylo-oligosacharide in an effective amount for regulating the functions of the intestines, preferably daily 0.4-7 g and the composition has symbiotic function and scarcely reduces viable cell number of bifidobacterium during storage, and the composition is compact and readily ingestible.

Description

Detailed Description of the Invention

[0001]

TECHNICAL FIELD The present invention relates to foods and drinks containing bifidobacteria and xylooligosaccharides. More specifically, in order to improve the in vivo utilization of Bifidobacterium, which is useful in intestinal regulation, and particularly Bifidobacterium longum species useful for humans, xylooligosaccharide, an oligosaccharide that can be assimilated by Bifidobacterium The present invention relates to a food / beverage containing an effective amount of the compound, increasing the stability in the food / beverage, and compacting the formulation to facilitate daily intake of Bifidobacterium and xylooligosaccharide.

[0002]

2. Description of the Related Art It is said that the surface of the intestine is made up of several fine folds, and when stretched widely, it is equivalent to 1.5 tennis courts, which is about 200 times as large as the outer skin. The intestine is a very important organ for life support because it takes in nutrients from the outside environment through the surface of the intestine and excretes some waste products generated in body tissues. The intestine also plays a role as a breakwater that protects against external enemies such as bacteria such as O-157, viruses, and foreign substances, and is very important for maintaining health.

It is known that more than 100 kinds and 100 trillion bacteria are resident on the surface of the intestine, and in general, good bacteria such as bifidobacteria and lactic acid bacteria, and Clostridium perfringens, Bacteroides, Staphylococcus aureus, Classified as bad bacteria such as E. coli.

[0004] The intestinal flora of infants is dominated by good bacteria such as Bifidobacterium, but it is known that the beneficial bacteria decrease with age and the proportion of bad bacteria increases, and maintenance of the intestinal flora is known.・ Management is considered to be very important for maintaining good health. Based on such knowledge, it is considered that the lactic acid bacterium, which is excellent in colonization and growth in the intestine, is always dominant in the intestinal flora in a good balance. Is used as probiotics.

However, there are various types of lactic acid bacteria,
Not all of them settle in the human intestine. In other words, even if taken orally, there are only a limited number of lactic acid bacteria that are resistant to acids such as gastric juice and bile, reach the intestines alive, and have good compatibility with the intestinal tract. Further, even if it is established, if the ingestion of lactic acid bacteria is stopped, the intestinal flora tends to be restored again, which is also a problem.

Further, probiotics are effective only when they are viable cells, and therefore, when the viable cells are dried to form granules, powders or capsules, damage to the cells such as a rapid change in osmotic pressure is caused. A buffer component is added to reduce the amount. However, the survival time of viable cells in the product is not always long depending on the formulation, and as a result, the effectiveness of the product varies, which makes it difficult to maintain an effective viable cell count in the formulation. There is a problem.

[0007] On the other hand, as a substance that significantly proliferates beneficial bacteria such as Bifidobacteria that naturally inhabit the body, various oligosaccharides, plant fibers, etc. are used as prebiotics, and functional foods for oral intake are also used. . Examples of oligosaccharides used as prebiotics are fructooligosaccharides (J. Appl. Microbiol., Vol.85, No.4, p769-
777, 1998) and xylooligosaccharides (JP-A-63-11)
2979). However, prebiotics alone have a problem that the effect is limited when the balance of the intestinal flora is biased toward bad bacteria.

[0008] Therefore, in order to positively increase the lactic acid bacteria in the intestine, recently, a synbiotic product in which a living bacterium having a probiotic function and an oligosaccharide having a prebiotic function are mixed is widely used. , Powder, capsules or tablets.

An example of prebiotics to be mixed is fructooligosaccharide. Fructo-oligosaccharide is a sucrose with 1,4-linked fructose, which is selectively assimilated by useful bacteria in the intestine, and is not digested or absorbed in the body, and therefore contributes greatly to the improvement of intestinal flora. It has been. However, fructooligosaccharides are not stable enough, especially when stored for a long time in an acidic solution, they change into glucose, fructose and sucrose,
There is a problem that the physiological activity is also reduced. Further, since fructooligosaccharides are less assimilated by useful bacteria than xylooligosaccharides, it is necessary to ingest a larger amount than xylooligosaccharides in order to obtain the effect. This is considered to have poor stability under acidic conditions such as gastric juice.

In addition, granules, powders, or capsules are often found in the dosage forms of synbiotic products using fructooligosaccharides, but the effect of oligosaccharides as a prebiotic function is weak, so in order to take an effective amount. There is a problem that the volume of the product becomes large, and there is a problem that an effective amount of oligosaccharide cannot be blended in a composition which has a compact volume and facilitates daily intake.

[0011]

DISCLOSURE OF THE INVENTION The present invention provides a composition for oral ingestion, which is based on the intestinal regulating action of bifidobacteria and is useful as a compact and preservative symbiotic product.

[0012]

Means for Solving the Problems As a result of intensive studies by the present inventors, when xylooligosaccharides were added to a composition for oral ingestion of bifidobacteria, particularly longum species, the viable count of bifidobacteria decreased during the storage period of the composition. It has been found that can suppress. Conventionally, such effects have not been known for oligosaccharides. Furthermore, xylooligosaccharides exhibit a stool-improving effect and an intestinal flora-improving effect in a very small amount as compared with other oligosaccharides, and therefore the formulation volume can be made compact while containing an effective amount. .

That is, the present invention is a composition for oral ingestion containing xylooligosaccharide and bifidobacteria. More specifically, a composition for oral ingestion of bifidobacteria, preferably longum seeds, is mixed with an effective amount of xylooligosaccharides for intestinal regulation, preferably 0.4 to 7 g per daily dose, and has a synbiotic function. A composition for oral ingestion of Bifidobacteria, characterized in that it has a small decrease in the number of viable Bifidobacteria during storage, is compact, and is easy to take.

Xylooligosaccharides are obtained by degrading xylan or hemicellulose. The source of xylan is widely demanded from the natural world, but particularly corn cob / cotton seed meal having a high xylan content, malt meal / rice straw obtained in large amounts as an industrial by-product, and the like are suitable. Xylan can be decomposed by a physical treatment such as an enzymatic treatment or an explosion treatment, or a combination thereof. The production of xylooligosaccharides by decomposing such xylan can be easily carried out by referring to literatures, for example, JP-A-63-11297.
No. 9.

In the xylooligosaccharide, xylose, which is a pentasaccharide, is linked by β-1,4 bond. If xylobiose (degree of polymerization 2), β-D-xylopyranosyl-
If it is (1 → 4) -D-xylopyranose and xylotriose (polymerization degree 3), β-D-xylopyranosyl- (1 → 4) -D-xylopyranosyl- (1 → 4)-
It is D-xylopyranose. The degree of polymerization of the xylooligosaccharide obtained by the decomposition of xylan is in the range of 1 to 10, but the xylooligosaccharide used in the present invention is a xylobiose (degree of polymerization 2) in which two molecules of xylose are linked with β-1,4.
Is preferably the main component (preferably containing 69% or more).

The amount of xylo-oligosaccharide blended is such that the bifidobacteria can be stably retained in the composition of the present invention and a decrease in the viable cell count during storage of the composition can be prevented. According to the study of the present inventors, when xylooligosaccharides are mixed in a ratio of 2: 1 to 100: 1 by dry weight with respect to Bifidobacteria (xylooligosaccharides: Bifidobacteria), the xylooligosaccharides can be stored in a composition for oral intake. It was found that it imparts the stability of Bifidobacterium. Therefore, in the present invention, the xylooligosaccharide can be mixed with the bifidobacteria in any ratio within the above range. However, preferably, the amount of xylo-oligosaccharide blended is an amount that promotes the intestinal function as a prebiotic when the composition is orally ingested. From the effect, it is appropriate that the necessary amount of xylooligosaccharide for exerting the effect of prebiotic is 0.4 to 10 g, preferably 0.4 to 7 g, and particularly preferably about 0.7 g as a daily dose. is there. When the amount of xylo-oligosaccharide is increased more than this, the volume of the composition ingestion unit becomes large, which is inconvenient to use as a functional food, and when the amount of xylo-oligosaccharide is large, the intestinal action is improved rather than soft stool. Can cause

The bifidobacteria used in the composition of the present invention are
Any bacterial species that is expected to have an intestinal regulating effect by oral ingestion may be used. Among other things, the longum species (Bifidobacterium longum)
Bifidobacterium is highly resistant to gastric acid, the ratio of the number of viable bacteria that reach the intestine when ingested is high, and the frequency of detection from the human intestine is high and the intestinal colonization is high. In addition, since xylooligosaccharides have a high assimilation property and can easily grow after fixation, they are particularly preferable for use in the present invention. Bifidobacteria of the longum species are commercially available for oral intake from a number of manufacturers (for example, can be purchased from Kyowa Hakko Co., Ltd.), but if necessary, ATCC (ATCC
15707).

There is no particular limitation on the amount of Bifidobacterium in the composition, but typically, 5 × 10 ⁸ to 1 × 10 ¹² CFU (colony forming unit) is used as the viable cell number per daily dose. Included, preferably 1 × 10 ^{9 to} 5 × 10 ¹¹ CF
U, particularly preferably 3.5 × 10 ⁹ CFU of Bifidobacterium.

The composition of the present invention may be a composition for any purpose for orally ingesting bifidobacteria, and may be, for example, food and drink, health food, functional food, pharmaceutical composition and the like. In any application, the form of the composition is
Examples include tablets, pills, capsules, granules, powders, and powders to be dispersed in a liquid just before use. A particularly preferred form is
These are tablets and granules such as tablets.

To mix xylooligosaccharides into Bifidobacteria, xylooligosaccharides prepared by fluidized bed granulation and the like and dry live cells are mixed, and other compounding ingredients (excipients, etc.) are added if necessary. , To obtain the desired composition.

The composition of the present invention comprises, in addition to bifidobacteria and xylooligosaccharides, a carrier, an excipient, a binder, a disintegrating agent, a dispersant, which can be used in foods and / or pharmaceuticals, depending on the purpose and application. Colorants, fragrances, lubricants and the like can be added. Further, the probiotics of the composition may include lactic acid bacteria, butyric acid bacteria, etc. in addition to Bifidobacterium.

The volume of the ingestion unit of the composition of the present invention can be appropriately changed. For example, in the case of granules, it is 1 as a mixed composition of lyophilized live lactic acid bacteria, xylo-oligosaccharide and an excipient. The amount per package is 0.5 to 3.0 g, preferably 1.0 to 2.5 g, and particularly preferably about 2 g.

[0023]

EFFECTS OF THE INVENTION The composition of the present invention has a symbiotic function by adding a xylooligosaccharide to bifidobacteria, which is easy to put into practical use, and has a small decrease in the number of viable bifidobacteria during storage and is compact. A composition for oral ingestion of bifidobacteria, which is characterized by being easy to take, can be produced. Since the composition of the present invention has little fluctuation in the viable cell count of Bifidobacterium during storage, it can exhibit a stable intestinal regulating effect for a long period of time. The compactness of the product provides the advantage that it can be taken easily even by elderly people and young children who have swallowing problems.

[0024]

The present invention will be described in detail below with reference to examples, but the invention is not limited thereto.

Example 1 A formulation was prepared with the following formulation. First, dry xylooligosaccharides and excipient granules prepared by fluidized bed granulation were mixed with dry viable cells, and individually packaged in a stick shape using an aluminum pouch.

Dried viable cells (longum species, Kyowa Hakko Co., Ltd.) 0.095 g Excipient 1.105 g Xylo-oligosaccharide 0.70 g 1.9 g Longum bacterial load: 3.5 x 10 ⁹ cells / 1.9 g * Excipients: dextrin (Sanmatsu Industry Co., Ltd.), sucrose fatty acid ester (Daiichi Kogyo Seiyaku Co., Ltd.), starch (Japan Food Processing Co., Ltd.), cellulose (Asahi Chemical Industry Co., Ltd.), maltitol ( Reduced maltose syrup, Nikken Chemical Co., Ltd. Example 2 In order to confirm the stability of the synbiotic product of the present invention produced in Example 1, the number of viable bacteria in the product was measured. The product was stored at 40 ° C and 75% RH for 4 weeks (constant temperature and humidity machine: Yamato Kagaku Co., Ltd.), and the physiological saline suspension of the product was plated on a bifidobacteria-selective (BS) agar medium. It was measured by anaerobic culturing at 37 ° C for 3 days and counting the number of colonies generated on the medium. The results are shown in Table 1.

[0027]

[Table 1] Table 1 Viability count stability test Initial 1 2 3 4 weeks ^{4.2x10 9 2.5x10 9 3.4x10 9 2.3x10 9} 1.4x10 9 (cells / g)

─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. ⁷ Identification code FI theme code (reference) A61P 1/14 A61P 1/14 F term (reference) 4B018 MD31 MD87 ME11 4C086 AA01 AA02 EA01 MA02 MA04 MA07 MA34 MA52 NA05 NA09 ZA73 4C087 AA01 AA02 BC60 MA02 MA34 MA52 NA05 NA09 ZA73

Claims (12)

[Claims] 1. A composition for oral ingestion containing xylooligosaccharide and bifidobacteria. 2. The composition according to claim 1, wherein the content of xylooligosaccharide is an effective amount for intestinal regulation. 3. The composition according to claim 1, wherein the content of the xylooligosaccharide as a daily dose is about 1 g or less. 4. Bifidobacte is a longum species.
The composition according to any one of claims 1 to 3, which is a rium longum). 5. A xylo-oligosaccharide is added to suppress the decrease in the number of viable Bifidobacteria during storage.
A composition for oral administration of Bifidobacterium. 6. The composition according to claim 5, wherein the content of xylooligosaccharide is an effective amount for intestinal regulation. 7. The composition according to claim 5, wherein the content of the xylooligosaccharide as a daily dose is about 1 g or less. 8. A bifidobacterium is a longum species (Bifidobacte).
8. The composition according to claim 5, which is a rium longum). 9. A method for suppressing a decrease in the number of viable bacteria of Bifidobacterium during storage of the composition by adding xylooligosaccharide to the composition for oral intake of Bifidobacterium. 10. The composition according to claim 9, wherein the content of xylooligosaccharide is an effective amount for intestinal regulation. 11. The method according to claim 9 or 10, wherein the content of the xylooligosaccharide as a daily dose is about 1 g or less. 12. The bifidobacterium is a longum species (Bifidobac
terium longum).